Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib Plus Anastrozole in HR+/HER2- Metastatic or Recurrent Breast Cancer
NCT07164976Phase 2Recruiting
- Sponsor
- Nagoya City University
- Start
- Oct 2025
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ribociclib in breast cancer, sponsored by Nagoya City University. Started Oct 2025; status: recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07164976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07164976.